Chronic Inflammatory Demyelinating Polyneuropathy Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight

DelveInsight's "Chronic Inflammatory Demyelinating Polyneuropathy Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Chronic Inflammatory Demyelinating Polyneuropathy, historical and forecasted epidemiology as well as the Chronic Inflammatory Demyelinating Polyneuropathy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Chronic Inflammatory Demyelinating Polyneuropathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Inflammatory Demyelinating Polyneuropathy Market Forecast
https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Chronic Inflammatory Demyelinating Polyneuropathy Market Report:
• The Chronic Inflammatory Demyelinating Polyneuropathy market size was valued ~USD 1.3 billion in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).
• In June 2025, Japan's Ministry of Health, Labour and Welfare (MHLW) has awarded orphan drug designation to riliprubart, a monoclonal antibody that specifically inhibits activated C1s in the classical complement pathway for patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Despite existing treatments, many CIDP patients continue to experience residual symptoms such as weakness, numbness, and fatigue, which can result in long-term complications and reduced quality of life. Around 30% of CIDP patients do not respond to standard therapies. The MHLW grants orphan drug status to medicines targeting rare diseases or conditions with unmet medical needs. Currently, approximately 4,000 individuals in Japan are diagnosed with CIDP.
• In June 2025, Amsterdam, the Netherlands - argenx SE (Euronext & Nasdaq: ARGX), a global immunology company focused on improving outcomes for individuals with severe autoimmune disorders, announced that the European Commission (EC) has approved VYVGART® (efgartigimod alfa) 1000 mg for subcutaneous (SC) injection as a standalone therapy for adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP) following prior corticosteroid or immunoglobulin treatment. VYVGART SC is available in vials or prefilled syringes and can be administered by patients, caregivers, or healthcare professionals. The treatment begins with a weekly dosing schedule, which can be adjusted to every other week based on clinical assessment.
• In May 2025, Nuvig Therapeutics, Inc. ("Nuvig"), a private biotechnology firm focused on developing innovative immunomodulatory therapies for inflammatory autoimmune diseases, announced that the first patient has been treated in its Phase 2 clinical trial assessing NVG-2089 in individuals with chronic inflammatory demyelinating polyneuropathy (CIDP). The company also revealed plans to present Phase 1 study results of NVG-2089 in healthy volunteers at the 2025 Peripheral Nerve Society (PNS) Annual Meeting.
• In January 2025, A recent study published in Annals of Clinical and Translational Neurology reported that, based on a retrospective cohort analysis in China, a simplified regimen using low-dose rituximab (Rituxan; Genentech/Biogen) demonstrated better efficacy and safety compared to standard therapy in treating patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
• In September 2024, Kine Sciences administered the first dose in its Phase Ib/IIa clinical trial of KINE-101, a novel nano peptide developed for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). KINE-101 functions by activating Treg cells to regulate both humoral and cell-mediated immune responses. This milestone follows the successful completion of a Phase I study in October last year, which confirmed KINE-101's strong safety profile.
• In September 2024, argenx SE (Euronext & Nasdaq: ARGX), a global immunology company dedicated to enhancing the lives of individuals with severe autoimmune diseases, has announced the publication of the pivotal ADHERE Study in The Lancet Neurology. This study represents the largest clinical trial conducted to date on chronic inflammatory demyelinating polyneuropathy (CIDP), a rare, debilitating, and often progressive immune-mediated neuromuscular disorder affecting the peripheral nervous system.
• In March 2024, HYQVIA® (immune globulin infusion 10%) is a liquid medication that combines a 10% concentration of immune globulin with recombinant human hyaluronidase PH20 (rHuPH20) enzyme, designed for the treatment of primary immunodeficiency (PI) and chronic inflammatory demyelinating polyneuropathy (CIDP).
• In 2023, the CIDP market size in the U.S. was around USD 1,382 million, with expected growth driven by the introduction of emerging therapies.
• In 2023, the total market size of the EU4 and the UK was estimated at approximately USD 363 million, accounting for nearly 20% of the total market revenue across the 7MM.
• In 2023, the UK had the largest market size among the EU4 and the UK, reaching approximately USD 88 million, followed closely by Germany at around USD 87 million. In contrast, Spain had the smallest market, valued at nearly USD 46 million.
• In 2023, Japan's CIDP market size was around USD 35 million, with projections indicating growth throughout the forecast period (2024-2034).
• In 2023, the U.S. had the highest number of diagnosed prevalent cases of CIDP, totaling around 30,230, with projections indicating an increase by 2034.
• In 2023, the UK recorded the highest number of diagnosed prevalent cases of CIDP among the EU4 and the UK, with approximately 3,250 cases, followed by Germany with around 3,174 cases. Conversely, Spain had the lowest prevalence, with nearly 1,691 cases.
• In 2023, Japan had around 2,045 diagnosed prevalent cases of CIDP, with projections indicating growth by 2034.
• In 2023, the U.S. recorded around 15,417 cases of typical CIDP and approximately 14,813 cases of atypical CIDP among the subtype-specific cases.
• In 2023, Japan's diagnosed prevalent cases of CIDP were distributed across different age groups as follows: approximately 41 cases in ages 0-19, 82 cases in ages 20-39, 798 cases in ages 40-59, 900 cases in ages 60-79, and 225 cases in those aged 80 and older.
• Key CIDP Companies: Takeda, Argenx, Sanofi, Janssen Research and Development, Immunovant Sciences GmbH, HanAll Pharma, Roivant Sciences, Shire, Argenx, Sanofi, Nihon Pharmaceutical, Immunovant Sciences, Octapharma, CSL Behring, Janssen Research, Novartis, Biogen, UCB Biopharma, Takeda, MedDay Pharmaceuticals, Teijin Pharma, Pfizer, Octapharma, Momenta Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Kedrion, Grifols, Bio Products Laboratory, Baxter, GeNeuro Pharmaceuticals, and others
• Key CIDP Therapies: HYQVIA (Immune Globulin Infusion 10% [Human] with Recombinant Human Hyaluronidase), VYVGART HYTRULO (Efgartigimod Alfa and Hyaluronidase-Qvfc), GAMMAGARD LIQUID/KIOVIG (Immune Globulin Infusion [Human] 10% Solution), Riliprubart (SAR445088), Nipocalimab, Batoclimab (HL161), Efgartigimod, SAR445088, NPB-01, Batoclimab, Panzyga, IgPro20, Nipocalimab, Fingolimod, Interferon Beta-1a, Rozanolixizumab, TAK-771, MD1003, and others
• The Chronic Inflammatory Demyelinating Polyneuropathy epidemiology based on gender analyzed that CIDP are more prominent in males in comparison to females.
• The CIDP market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Inflammatory Demyelinating Polyneuropathy pipeline products will significantly revolutionize the Chronic Inflammatory Demyelinating Polyneuropathy market dynamics.

Chronic Inflammatory Demyelinating Polyneuropathy Overview
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare neurological disorder in which the immune system attacks the myelin sheath-the protective covering of the peripheral nerves-leading to nerve damage. This causes progressive weakness, numbness, and tingling in the arms and legs. CIDP develops gradually over at least eight weeks and can result in difficulty walking, loss of reflexes, and fatigue. While the exact cause is unknown, it is considered an autoimmune condition. Treatments focus on reducing immune system activity and managing symptoms, commonly using corticosteroids, intravenous immunoglobulin (IVIg), or plasma exchange, often improving strength and mobility over time.

Get a Free sample for the CIDP Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology Segmentation:
The Chronic Inflammatory Demyelinating Polyneuropathy market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Chronic Inflammatory Demyelinating Polyneuropathy
• Prevalent Cases of Chronic Inflammatory Demyelinating Polyneuropathy by severity
• Gender-specific Prevalence of Chronic Inflammatory Demyelinating Polyneuropathy
• Diagnosed Cases of Episodic and Chronic Chronic Inflammatory Demyelinating Polyneuropathy

Download the report to understand which factors are driving Chronic Inflammatory Demyelinating Polyneuropathy epidemiology trends @ Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology Forecast
https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Chronic Inflammatory Demyelinating Polyneuropathy Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Inflammatory Demyelinating Polyneuropathy market or expected to get launched during the study period. The analysis covers Chronic Inflammatory Demyelinating Polyneuropathy market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

CIDP Therapies and Key Companies
• HYQVIA (Immune Globulin Infusion 10% [Human] with Recombinant Human Hyaluronidase): Takeda
• VYVGART HYTRULO (Efgartigimod Alfa and Hyaluronidase-Qvfc): Argenx
• GAMMAGARD LIQUID/KIOVIG (Immune Globulin Infusion [Human] 10% Solution): Takeda
• Riliprubart (SAR445088): Sanofi
• Nipocalimab: Janssen Research and Development
• Batoclimab (HL161): Immunovant Sciences GmbH/HanAll Pharma/Roivant Sciences
• HyQvia: Shire
• Efgartigimod: Argenx
• SAR445088: Sanofi
• NPB-01: Nihon Pharmaceutical
• Batoclimab: Immunovant Sciences
• Panzyga: Octapharma
• IgPro20: CSL Behring
• Nipocalimab: Janssen Research
• Fingolimod: Novartis
• Interferon Beta-1a: Biogen
• Rozanolixizumab: UCB Biopharma SRL
• TAK-771: Takeda
• MD1003: MedDay Pharmaceuticals

Discover more about therapies set to grab major Chronic Inflammatory Demyelinating Polyneuropathy market share @ Chronic Inflammatory Demyelinating Polyneuropathy Treatment Landscape
https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

CIDP Market Strengths
• The prevalence of autoimmune diseases has increased dramatically, paving the way for the growth of the CIDP market. Rise in the prevalence has driven the demand for effective research and development of effective treatments against the disease, therefore many key players are actively contributing their investments.
• Numerous public and private organizations launched initiatives and supporting funding for R&D activities that produced positive results in the area of CIDP.
• In recent years there has been a surge in the novel targets as potential therapeutic alternatives to traditional treatments.

CIDP Market Opportunities
• Various new drugs have been launched into the market in recent years have also boosted the growth of market
• Active research of immunoglobulin for the autoimmune diseases will also laid to growth in the market of CIDP.
• Fc receptors antagonists are developing which are hopeful candidates with for the effective treatment of CIDP.

Scope of the Chronic Inflammatory Demyelinating Polyneuropathy Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Chronic Inflammatory Demyelinating Polyneuropathy Companies: Takeda, Argenx, Sanofi, Janssen Research and Development, Immunovant Sciences GmbH, HanAll Pharma, Roivant Sciences, Shire, Argenx, Sanofi, Nihon Pharmaceutical, Immunovant Sciences, Octapharma, CSL Behring, Janssen Research, Novartis, Biogen, UCB Biopharma, Takeda, MedDay Pharmaceuticals, Teijin Pharma, Pfizer, Octapharma, Momenta Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Kedrion, Grifols, Bio Products Laboratory, Baxter, GeNeuro Pharmaceuticals, and others
• Key Chronic Inflammatory Demyelinating Polyneuropathy Therapies: HYQVIA (Immune Globulin Infusion 10% [Human] with Recombinant Human Hyaluronidase), VYVGART HYTRULO (Efgartigimod Alfa and Hyaluronidase-Qvfc), GAMMAGARD LIQUID/KIOVIG (Immune Globulin Infusion [Human] 10% Solution), Riliprubart (SAR445088), Nipocalimab, Batoclimab (HL161), Efgartigimod, SAR445088, NPB-01, Batoclimab, Panzyga, IgPro20, Nipocalimab, Fingolimod, Interferon Beta-1a, Rozanolixizumab, TAK-771, MD1003, and others
• Chronic Inflammatory Demyelinating Polyneuropathy Therapeutic Assessment: Chronic Inflammatory Demyelinating Polyneuropathy current marketed and Chronic Inflammatory Demyelinating Polyneuropathy emerging therapies
• Chronic Inflammatory Demyelinating Polyneuropathy Market Dynamics: Chronic Inflammatory Demyelinating Polyneuropathy market drivers and Chronic Inflammatory Demyelinating Polyneuropathy market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Chronic Inflammatory Demyelinating Polyneuropathy Unmet Needs, KOL's views, Analyst's views, Chronic Inflammatory Demyelinating Polyneuropathy Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.